Peptides for Post-Concussion Recovery — Neuroprotection, Neuroinflammation, and Brain Repair

How peptide Targets Peptides for Post-Concussion Recovery

Concussion initiates a complex secondary injury cascade that extends far beyond the initial mechanical impact. Within minutes, glutamate excitotoxicity, calcium influx, and mitochondrial dysfunction begin damaging neurons that survived the primary trauma. Over the following hours and days, microglial activation drives neuroinflammation, the blood-brain barrier becomes compromised, and neurotrophic factor production shifts from repair-promoting to inflammatory. This secondary cascade — not the initial impact — is responsible for most persistent post-concussion symptoms including headache, brain fog, mood disturbance, and light sensitivity. Peptides intervene at multiple points in this cascade.

Cerebrolysin is the most extensively studied neuroprotective peptide mixture, with clinical trial data in traumatic brain injury. It provides a combination of neurotrophic factors and active peptide fragments that cross the blood-brain barrier and support neuronal survival, synaptic repair, and neurogenesis. Multiple randomized trials have demonstrated improved cognitive outcomes when administered in the acute-to-subacute post-TBI period. Semax, a synthetic analog of ACTH(4-10), upregulates brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression — two signals critically depleted after concussion. It also modulates the melanocortin system, which has direct anti-inflammatory effects in the central nervous system. Russian clinical data supports its use in cerebrovascular injury, though controlled trials specific to sports concussion are lacking.

Selank complements Semax by targeting the anxiety, sleep disruption, and emotional dysregulation that commonly accompany post-concussion syndrome. It modulates GABAergic signaling and reduces inflammatory cytokine expression in the CNS, addressing both the neuropsychiatric symptoms and the underlying neuroinflammation simultaneously. BPC-157 has demonstrated blood-brain barrier protective effects in preclinical models and promotes angiogenesis — the formation of new blood vessels — which is critical for restoring adequate cerebral perfusion to injured brain regions. Its gut-brain axis effects may also be relevant, as gastrointestinal dysfunction is an underrecognized component of post-concussion syndrome.

The evidence base varies significantly across these peptides. Cerebrolysin has the strongest clinical trial support for TBI. Semax has regulatory approval in Russia for cerebrovascular conditions. Selank and BPC-157 have compelling preclinical data but limited controlled human trials specific to concussion. A rational post-concussion peptide protocol would prioritize evidence-backed interventions while recognizing that the biological rationale for adjunctive peptides is sound even where large-scale human data is still accumulating. All peptide use should be considered complementary to — not a replacement for — standard concussion management including cognitive rest, graded return to activity, and treatment of specific symptoms.